The Point of Care Molecular Diagnostics Market research study offers a complete examination of the market, covering its present performance, expected growth trends, and competitive framework. The report includes a breakdown of market size, share distribution, and demand analysis, supported by key insights into technological shifts and consumer preferences. With a strong focus on industry challenges and opportunities, it equips stakeholders with actionable knowledge to anticipate changes and maximize growth potential.

Additionally, the report provides segmentation insights based on product type, end-user application, and geography, helping businesses identify high-growth segments. It also considers the impact of regulations, innovation, and global market dynamics, offering a forward-looking perspective. This comprehensive coverage ensures that businesses and investors can make informed decisions and craft strategies for long-term market advantage.

Point of Care Molecular Diagnostics Market Size

• The global point of care molecular diagnostics market size was valued at USD 11.97 billion in 2024 and is expected to reach USD 43.94 billion by 2032, at a CAGR of 13.40% during the forecast period
• The market growth is primarily driven by the increasing prevalence of infectious diseases, rising demand for rapid and accurate diagnostic testing, and advancements in molecular diagnostic technologies.
• In addition, the expansion of decentralized healthcare, rising adoption of point of care testing in hospitals and clinics, and growing awareness about early disease detection are significantly propelling the market’s expansion worldwide. 

Get a comprehensive analysis and future outlook for the Point of Care Molecular Diagnostics. View the complete report: https://www.databridgemarketresearch.com/reports/global-point-of-care-molecular-diagnostics-market

Point of Care Molecular Diagnostics Market Analysis

• Point of care molecular diagnostics enable rapid, accurate detection of diseases at or near the patient site, playing a critical role in improving healthcare outcomes in both clinical and remote settings
• The market growth is driven by the increasing prevalence of infectious diseases, rising demand for timely diagnosis, and technological advancements in molecular testing platforms that offer portability, ease of use, and faster results
• North America dominates the point of care molecular diagnostics market with the largest revenue share of 38.5% in 2024, supported by advanced healthcare infrastructure, significant R&D investments, and widespread adoption in hospitals and clinics. The U.S. leads this growth with increasing deployment of molecular diagnostic devices for diseases such as COVID-19, cancer, and genetic disorders
• Asia-Pacific is expected to be the fastest-growing region in the point of care molecular diagnostics market during the forecast period, propelled by improving healthcare access, growing government initiatives for disease control, and rising awareness of early diagnosis in countries such as China, India, and Japan
• The respiratory diseases segment is projected to dominate the market with a significant share of 42.3% in 2024, due to the high demand for rapid and accurate diagnosis of conditions such as COVID-19, influenza, and tuberculosis, which require timely intervention to reduce transmission and improve patient outcomes

Point of Care Molecular Diagnostics Market Dynamics

Driver

“Growing Demand Fueled by the Rise in Respiratory Diseases and the Need for Quick Diagnosis”

• The growing prevalence of respiratory diseases such as COVID-19, influenza, and tuberculosis is significantly driving demand for point of care molecular diagnostics, which provide fast and accurate results critical for timely treatment and infection control
  • For instance, in March 2024, Abbott launched the ID NOW COVID-19 rapid molecular test, enabling healthcare providers to deliver results in minutes at the point of care, enhancing patient management and reducing hospital burden
• Rising awareness among healthcare professionals and patients about the benefits of decentralized testing, including faster diagnosis and improved treatment outcomes, is further fueling market growth
• In addition, increasing government initiatives and funding to improve diagnostic infrastructure globally are accelerating the adoption of molecular diagnostic devices at point of care settings
• The ongoing technological advancements in molecular diagnostic platforms, such as portable devices and multiplex testing capabilities, are expanding their applications and driving market penetration across hospitals, clinics, and remote care facilities

The point of care molecular diagnostics industry is primarily led by well-established companies, including:

• Abbott (US)
• Siemens Healthineers AG (Germany)
• Quidel Corporation (US)
• F. Hoffman-La Roche Ltd. (Switzerland)
• Danaher. (US)
• BD (US)
• Chembio Diagnostics (US)
• EKF Diagnostics (UK)
• Trinity Biotech plc (Ireland)
• Instrumentation Laboratory (US)
• Nova Biomedical (US)
• PTS Diagnostics (US)
• Sekisui Diagnostics (US)
• Thermo Fisher Scientific (US)
• bioMérieux S.A. (France)
• DiaSorin S.p.A (Italy)
• AccuBioTech Co., Ltd. (China)
• Meridian Bioscience (US)
• Biocartis Bioscience (Europe)
• GeneSTAT Molecular Diagnostics, LLC (US)
• Terumo Corporation (Japan)
• Grifols, S.A (Spain)

Latest Developments in Global Point of Care Molecular Diagnostics Market

• In February 2025, Avitia launched an AI-powered cancer diagnostics platform, enabling rapid, cost-effective testing at the point of care. This innovation enhances clinical decision-making, reduces costs, and accelerates treatment timelines. Already deployed across North America and Southeast Asia, Avitia’s platform advances precision oncology
• In January 2025, Roche received FDA 510(k) clearance and a CLIA waiver for its cobas liat multiplex assays, enabling point-of-care STI testing. These assays allow clinicians to diagnose chlamydia, gonorrhea, and Mycoplasma genitalium using a single sample, delivering results in 20 minutes. The technology enhances rapid treatment decisions and reduces follow-up delays
• In May 2025, Sherlock Bio has begun clinical trials for its over-the-counter rapid STI test, designed to detect chlamydia and gonorrhea with self-collected swabs. The test delivers results within 30 minutes, improving accessibility and reducing discomfort compared to traditional lab testing. The company aims for a mid-2025 launch, pending FDA approval
• In May 2024, Molbio launched TruSight, an AI-powered point-of-care platform for hematology applications, including complete blood count (CBC), malaria detection, and sickle cell disease screening. Designed for resource-limited settings, TruSight enhances diagnostic accuracy and accessibility, supporting rapid blood analysis with advanced AI algorithms. This innovation aims to improve clinical efficiency while reducing testing barriers
• In December 2024, Labcorp introduced a molecular diagnostic test for the H5N1 bird flu virus, supporting rapid detection amid a multistate outbreak in the U.S. The test, developed with CDC collaboration, enhances public health preparedness by enabling physicians to diagnose infections quickly using nasopharyngeal swabs 

Frequently Asked Questions

• What were the historical performance and growth trends of the Point of Care Molecular Diagnostics market?

• What is the current market value of Point of Care Molecular Diagnostics?

• What is the forecast CAGR and estimated market size in the future?

• How is the market classified by product type, usage, and region?

• Which regions are leading in adoption, and which show fastest growth?

• What demand factors are positively influencing the market?

• What limitations or risks might impact future development?

• What is the future outlook and business potential in the Point of Care Molecular Diagnostics industry?

Table of Contents

• Executive Summary

• Study Objectives

• Industry Overview

• Market Size Analysis

• Market Segmentation

• Key Market Trends

• Competitive Landscape

• Regional Insights

• Market Opportunities

• Future Outlook & Forecast

Browse More Reports:
Asia-Pacific Contract Manufacturing Market
Middle East and Africa Contract Manufacturing Market
North America CRISPR Gene Detection and Diagnostic Market
Asia-Pacific CRISPR Gene Detection and Diagnostic Market
Europe CRISPR Gene Detection and Diagnostic Market
Middle East and Africa CRISPR Gene Detection and Diagnostic Market
U.S. and Europe Crypto Asset Management Market
U.S. Database Automation Market
Asia-Pacific Dental Silver Diamine Fluoride (SDF) Market
North America Dental Silver Diamine Fluoride (SDF) Market
Europe Dental Silver Diamine Fluoride (SDF) Market
Middle East and Africa Dental Silver Diamine Fluoride (SDF) Market
Asia-Pacific Dry Eye Syndrome Treatment Market
Europe Dry Eye Syndrome Market
Middle East and Africa Dry Eye Syndrome Treatment Market
North America Dry Eye Syndrome Treatment Market
Europe Earplugs Market
North America Earplugs Market
Asia-Pacific Earplugs Market
Middle East and Africa Earplugs Market

About Data Bridge Market Research:
An absolute way to forecast what the future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC: +653 1251 975
Email: [email protected]

"